文献速递肿瘤 PET/CT

FDG-PET/CT在转移性乳腺癌疗效评估中的作用

A role of FDG-PET/CT for response evaluation in metastatic breast cancer?
PubMed 文献 · Semin Nucl Med · 2022-05-04

本文综述FDG-PET/CT用于转移性乳腺癌疗效评估的证据。定量PET方法具有高预后价值,按RECIST与PERCIST标准评估时预测价值高于常规CT;FDG-PET/CT对进展和缓解的检出更敏感,而CT和骨显像更多判为稳定。回顾性研究提示较常规影像有生存获益,似源于更早发现进展;但尚无前瞻性多中心研究,需进一步研究后方能在指南中推荐。

要点

  • FDG-PET/CT定量方法在转移性乳腺癌中已证实具有高预后价值。
  • 按RECIST与PERCIST评估时,FDG-PET/CT预测价值高于常规CT。
  • 回顾性研究提示FDG-PET/CT较常规影像有生存获益,似源于更早发现进展。

核心结论

  • FDG-PET/CT对转移性乳腺癌疗效评估的准确性高于常规影像,但能否转化为患者获益尚需前瞻性多中心研究证实。
  • 回顾性研究提示FDG-PET/CT较常规影像有生存获益,似因更早发现进展而更早更换治疗。
  • 需改进基于神经网络建模的临床适用方法,以标准化整合定量信息并实现扫描间、患者间和机构间可比。
  • 在就未来临床指南推荐何种扫描得出明确结论前,需开展分析患者生存、生活质量及社会与患者成本的前瞻性多中心研究。

研究设计与样本

  • 本文为综述,围绕FDG-PET/CT在转移性乳腺癌疗效评估中的作用汇总现有证据。
  • 文中引用的生存获益证据来自一项回顾性研究。

主要发现

  • 采用定量PET方法时,FDG-PET/CT在转移性乳腺癌患者中已证实具有高预后价值。
  • 分别应用RECIST与PERCIST标准时,FDG-PET/CT的预测价值高于常规CT。
  • FDG-PET/CT的疗效分类对进展和缓解的检出更敏感,而CT和骨显像等常规影像更多判为稳定。
  • 回顾性研究提示,FDG-PET/CT用于疗效评估较常规影像有生存获益。
  • 生存获益似源于FDG-PET/CT较常规影像更早发现进展,从而更早更换治疗并可能使后续治疗线更有效。

关键数值与推荐

  • FDG-PET/CT可按照PERCIST所建议的方式半定量使用。
  • 常规影像的疗效评估采用RECIST标准,FDG-PET/CT采用PERCIST标准。

临床怎么用

  • FDG-PET/CT可按照PERCIST所建议的方式半定量用于疗效评估。
  • 在就未来临床指南推荐何种扫描得出明确结论前,需前瞻性多中心研究分析患者生存、生活质量及社会与患者成本。
  • 作者认为需改进基于神经网络建模的临床适用方法,以标准化整合定量信息并支持影像专家进行诊断性疗效评估。

局限性

  • 支持生存获益的证据来自回顾性研究。
  • 尚需前瞻性多中心研究分析患者生存、生活质量及社会与患者成本,之后才能就未来临床指南推荐何种扫描得出明确结论。
  • 仍需改进基于神经网络建模的临床适用方法,以实现扫描间、患者间和机构间可比。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Breast cancer prognosis is steadily improving due to early detection of primary cancer in screening programs and revolutionizing treatment development. In the metastatic setting, therapy improvements render breast cancer a chronic disease. Although FDG-PET/CT has emerged as a highly accurate method for staging metastatic breast cancer, there has been no change in response evaluation methods for decades. FDG-PET/CT has proven high prognostic values in patients with metastatic breast cancer when using quantitative PET methods. It has also shown a higher predictive value than conventional CT when applying the respective response evaluation criteria, RECIST and PERCIST. Response categorization using FDG-PET/CT is more sensitive in detecting progressive and regressive disease, while conventional imaging such as CT and bone scintigraphy deem stable disease more often. These findings reflect the higher accuracy of FDG-PET/CT for response evaluation in this patient group. But does the higher accuracy of FDG-PET/CT translate into a patient benefit when implementing it for monitoring response to palliative treatment? We have evidence of survival benefit from a retrospective study indicating the superiority of using FDG-PET/CT compared with conventional imaging for response evaluation in metastatic breast cancer patients. The survival benefit seems to result from earlier detection of progression with FDG-PET/CT than conventional imaging, leading to an earlier change in treatment with potentially better efficacy of the subsequent treatment line. FDG-PET/CT can be used semiquantitatively as suggested in PERCIST. However, we still need to improve clinically applicable methods based on neural network modeling to better integrate the quantitative information in a smart and standardized way, enabling relevant comparability between scans, patients, and institutions. Such innovation is warranted to support imaging specialists in diagnostic response assessment. Prospective multicenter studies analyzing patients' survival, quality of life, societal and patient costs of replacing conventional imaging with FDG-PET/CT are needed before firm conclusions can be drawn on which type of scan to recommend in future clinical guidelines.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hildebrandt MG, Naghavi-Behzad M, Vogsen M, et al. A role of FDG-PET/CT for response evaluation in metastatic breast cancer? Semin Nucl Med. 2022. PMID: 35525631. doi:10.1053/j.semnuclmed.2022.03.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。